Trials / Unknown
UnknownNCT04339400
A Study of TQ05105 Tablets in Subjects With Myeloproliferative Neoplasms
A Single-group, Open-label, Multicenter, Phase I Study of TQ05105 Tablets in Subjects With Myeloproliferative Neoplasms
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
TQ05105 is a JAK2 inhibitors and can be used to treat JAK2 target-related diseases. The activation of the JAK/STAT pathway is related to abnormal proliferation, obstruction of apoptosis, and differentiation disorder of leukemia cells which is caused by genetic abnormalities and viral infection.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TQ05105 | TQ05105 is a JAK2 inhibitor. |
Timeline
- Start date
- 2018-11-20
- Primary completion
- 2020-12-31
- Completion
- 2021-06-30
- First posted
- 2020-04-09
- Last updated
- 2020-04-09
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT04339400. Inclusion in this directory is not an endorsement.